Opus Genetics, Inc.
IRD
$4.91
-$0.28-5.40%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.16% | -20.38% | 159.17% | 155.41% | 154.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.16% | -20.38% | 159.17% | 155.41% | 154.41% |
| Cost of Revenue | 48.25% | -28.65% | -1.05% | 66.37% | 81.85% |
| Gross Profit | -140.23% | 34.90% | 36.87% | -16.08% | -25.49% |
| SG&A Expenses | -32.99% | 72.11% | 71.91% | 37.06% | 124.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.89% | -4.09% | 24.87% | 51.81% | 101.28% |
| Operating Income | -14.20% | -3.77% | -6.94% | -28.81% | -84.73% |
| Income Before Tax | 52.97% | -131.92% | 4.44% | -15.31% | -632.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.97% | -131.92% | 4.44% | -15.31% | -632.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.97% | -131.92% | 4.44% | -15.31% | -632.74% |
| EBIT | -14.20% | -3.77% | -6.94% | -28.81% | -84.73% |
| EBITDA | -14.10% | -3.63% | -6.79% | -28.67% | -84.79% |
| EPS Basic | 82.29% | 14.17% | 61.06% | 16.56% | -455.06% |
| Normalized Basic EPS | 12.80% | 14.17% | 61.04% | 16.47% | -12.57% |
| EPS Diluted | 82.29% | 14.17% | 61.06% | 16.56% | -455.06% |
| Normalized Diluted EPS | 12.80% | 14.17% | 61.04% | 16.47% | -12.57% |
| Average Basic Shares Outstanding | 165.44% | 170.17% | 145.39% | 38.19% | 32.04% |
| Average Diluted Shares Outstanding | 165.44% | 170.17% | 145.39% | 38.19% | 32.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |